![Martin Gouldstone](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Martin Gouldstone
Chief Executive Officer at
ONCE HLDG
Net worth: 3 978 $ as of 30/07/2026
Profile
Mr. Martin J.
Gouldstone is an Independent Non-Executive Chairman at ValiRx Plc, a Chief Executive Officer at Oncimmune Holdings Plc, an Independent Non-Executive Director at hVIVO Holdings Ltd. and a Chief Executive Officer at Oncimmune Germany GmbH.
He is on the Board of Directors at hVIVO Holdings Ltd. Mr. Gouldstone was previously employed as an Independent Non-Executive Director by hVIVO PLC, a Global Senior Vice President-Business Development by Owkin, Inc., a Chief Business Development Officer by Sensyne Health Ltd., a Chief Business Officer by BenevolentAI SA, a Partner by Results Healthcare, a Director-Corporate Advisory & Head-Life Sciences by BDO UK LLP, and a Director-Business Development by Sareum Ltd. He also served on the board at Orthopaedic Research UK and Novara Therapeutics Ltd.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
VALIRX PLC 0.15% | 20/11/2025 | 1,969,231 ( 0.15% ) | 3 978 $ | 30/07/2026 |
Martin Gouldstone active positions
| Companies | Position | Start |
|---|---|---|
| ONCE HLDG | Chief Executive Officer | 31/07/2023 |
| HVIVO PLC | Director/Board Member | 31/05/2022 |
| VALIRX PLC | Chairman | 24/07/2024 |
Oncimmune Germany GmbH
 Oncimmune Germany GmbH BiotechnologyHealth Technology Develops antibody and autoantibody biomarker discovery platform | Chief Executive Officer | - |
Former positions of Martin Gouldstone
| Companies | Position | End |
|---|---|---|
| HVIVO PLC | Director/Board Member | 04/06/2025 |
Orthopaedic Research UK
 Orthopaedic Research UK Miscellaneous Commercial ServicesCommercial Services Provides business support services | Director/Board Member | 29/02/2024 |
| SENSYNE HEALTH PLC | Corporate Officer/Principal | 30/04/2022 |
| BENEVOLENTAI S.A. | Corporate Officer/Principal | 31/12/2018 |
Results Healthcare
 Results Healthcare Investment ManagersFinance Provides advisory services | Corporate Officer/Principal | 31/05/2018 |
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
51
1st degree connections
12
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 12 |
|---|---|
ValiRx Plc
 ValiRx Plc Pharmaceuticals: MajorHealth Technology Develops novel technologies and products in oncology therapeutics and diagnostics | Health Technology |
hVIVO Holdings Ltd.
 hVIVO Holdings Ltd. Miscellaneous Commercial ServicesCommercial Services Provides medical research services | Commercial Services |
Sareum Ltd.
 Sareum Ltd. Drugstore ChainsRetail Trade Provides drug discovery services | Retail Trade |
Results Healthcare
Results Healthcare Investment ManagersFinance Provides advisory services | Finance |
Oncimmune Holdings Plc
 Oncimmune Holdings Plc BiotechnologyHealth Technology Provides cancer detection and diagnosis services | Health Technology |
Orthopaedic Research UK
Orthopaedic Research UK Miscellaneous Commercial ServicesCommercial Services Provides business support services | Commercial Services |
Owkin, Inc.
 Owkin, Inc. Packaged SoftwareTechnology Services Develops AI technology that accelerates drug discovery by combining multimodal patient data and large language models | Technology Services |
Sensyne Health Ltd.
 Sensyne Health Ltd. Miscellaneous Commercial ServicesCommercial Services Provides statistical analyses and advanced insights to the healthcare industry | Commercial Services |
BDO UK LLP
 BDO UK LLP Miscellaneous Commercial ServicesCommercial Services Provides tax, audit & assurance, advisory and business outsourcing services | Commercial Services |
hVIVO PLC
 hVIVO PLC Miscellaneous Commercial ServicesCommercial Services Provides pharmaceutical development services | Commercial Services |
Oncimmune Germany GmbH
Oncimmune Germany GmbH BiotechnologyHealth Technology Develops antibody and autoantibody biomarker discovery platform | Health Technology |
BenevolentAI SA
 BenevolentAI SA Packaged SoftwareTechnology Services Develops AI drug discovery platform to accelerate biopharma drug discovery | Technology Services |
- Stock Market
- Insiders
- Martin Gouldstone
